Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729462) titled 'A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine' on July 22.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Pfizer
Condition:
Preventive Treatment of Migraine
Intervention:
Drug: Rimegepant
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: July 29, 2026
Target Sample Size: 400
Countries of Recruitment:
United States
To know...